Relapsed small cell lung cancer: treatment options and latest developments

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2010 • 5,268 citations

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 • 2,376 citations

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

2009 • 2,274 citations

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

2006 • 1,745 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

2000 • 848 citations

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

2005 • 640 citations

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

2003 • 634 citations

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

2006 • 603 citations

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

1997 • 560 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

2007 • 356 citations

Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.

1996 • 275 citations

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

1998 • 275 citations

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

2001 • 236 citations

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

2008 • 236 citations

Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma

2008 • 229 citations

Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

2006 • 227 citations

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer

2008 • 185 citations

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

2009 • 185 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

2010 • 171 citations

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1987 • 155 citations

Small cell lung carcinoma (SCLC): the angiogenic phenomenon

2002 • 136 citations

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

2010 • 124 citations

Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3

2004 • 122 citations

Reinduction chemotherapy in small cell lung cancer

1987 • 121 citations

Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

1999 • 114 citations

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

2006 • 110 citations

A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex

1998 • 107 citations

A Phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma

1997 • 106 citations

Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.

2002 • 104 citations

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

1998 • 101 citations

Prognostic factors for limited-stage small cell lung cancer: A study of 284 patients

2009 • 92 citations

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

2009 • 85 citations

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

1998 • 72 citations

Small cell lung cancer

2006 • 72 citations

Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer

2001 • 68 citations

VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer

1984 • 68 citations

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

2003 • 61 citations

Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update

2004 • 58 citations

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

2012 • 55 citations

Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer

2006 • 55 citations

Hypoxia Inducible Factor-1alpha and Vascular Endothelial Growth Factor in Biopsies of Small Cell Lung Carcinoma

2009 • 53 citations

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

2009 • 53 citations

Tumor‐selective Distribution of an Active Metabolite of the 9‐Aminoanthracycline Amrubicin

1998 • 50 citations

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study

2001 • 49 citations

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

2006 • 48 citations

In vivo Efficacy and Tumor‐selective Metabolism of Amrubicin to Its Active Metabolite

1998 • 47 citations

Recurrent small cell lung cancer: Update

2003 • 46 citations

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer

2003 • 45 citations

Second-line chemotherapy for small-Cell Lung Cancer (SCLC)

2010 • 43 citations

Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)

2006 • 40 citations

Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients

2008 • 39 citations

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer.

1997 • 38 citations

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population

2011 • 36 citations

Could we expect to improve survival in small cell lung cancer?

2007 • 36 citations

Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer

2007 • 35 citations

Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer

2003 • 35 citations

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer

2008 • 34 citations

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

2004 • 32 citations

Small cell lung cancer and targeted therapies

2007 • 32 citations

Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.

1995 • 32 citations

A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer

2008 • 31 citations

Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study

2009 • 29 citations

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC lung cancer cooperative group

1993 • 29 citations

Phase II Trial of Gemcitabine/Irinotecan in Refractory or Relapsed Small-Cell Lung Cancer

2005 • 28 citations

Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer

2000 • 28 citations

Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Cancer

1988 • 28 citations

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

2008 • 26 citations

Combination Chemotherapy with Irinotecan and Ifosfamide as Second-Line Treatment of Refractory or Sensitive Relapsed Small Cell Lung Cancer: A Phase II Study

2003 • 25 citations

Small cell lung cancer in the elderly patient.

1997 • 23 citations

Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer

2007 • 18 citations

Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy

2012 • 15 citations

Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience.

1992 • 13 citations

Ambamustine in the Second-Line Treatment of Patients With Small-Cell Lung Cancer

2000 • 10 citations

P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studies

2003 • 9 citations

SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC).

2012 • 9 citations

Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC)

2006 • 4 citations

A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC).

2012 • 3 citations